Compare PASW & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PASW | ARTL |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.5M |
| IPO Year | N/A | N/A |
| Metric | PASW | ARTL |
|---|---|---|
| Price | $0.20 | $1.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 8.7M | 95.1K |
| Earning Date | 01-12-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,286,193.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $1.15 |
| 52 Week High | $5.40 | $28.60 |
| Indicator | PASW | ARTL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 56.54 |
| Support Level | N/A | $1.35 |
| Resistance Level | N/A | $1.77 |
| Average True Range (ATR) | 0.00 | 0.15 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 0.00 | 90.86 |
Ping An Biomedical Co Ltd formerly Majestic Ideal Holdings Ltd is a Cayman Islands-based holding company, conducting operations through its PRC subsidiary, NewBrand. The group is a provider of SCM services in the apparel industry, offering solutions for a broad range of yarn products, textiles, and finished garments. Its service offerings encompass every key aspect of the supply chain of textile products, such as market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. The group has two reportable segments, yarns and finished garments. The majority of its revenue is generated from the sale of yarns, including pure cashmere and cashmere-mix yarn, merino wool, cotton, and fancy yarn.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.